Hypoxia and Inflammatory Injury in Human Renovascular Hypertension

Summary

Current treatments for ARAS based on restoring blood flow alone have been unsuccessful at recovering kidney function. For this reason we are studying a stem cell product called "mesenchymal stem cells" or MSC. Mesenchymal stem cells (MSC) are grown from a person's own fat tissue (obtained as a fat biopsy) and infused back into the patient's own kidney. This study is also being done to determine if the MSC infusion prior to percutaneous transluminal renal angioplasty with stenting (PTRA) further enhances changes in single kidney blood flow and restoration of kidney function, as well as to assess the relationship between MSC dose and measures of kidney function.

Timeline

Start

2014-10-21

Primary completion

2020-09-25

Completion

2020-09-25

Publications

• Al Saeedi M, Abdurakhimova DA, Arabi T, Nyvad J, Oudih M, Xing L, Lu B, Zhang L, Zhu X, Misra S, Lerman A, Lerman LO. Association between CT-evaluated Poststenotic Dilatation in Human Renal Artery Stenosis and Kidney Release of MCP-1. Radiology. 2026 Apr;319(1):e252637. doi: 10.1148/radiol.252637.
• Lerman LO. Cell-based regenerative medicine for renovascular disease. Trends Mol Med. 2021 Sep;27(9):882-894. doi: 10.1016/j.molmed.2021.06.004. Epub 2021 Jun 25.

Drugs

Indications